ALKS 4230

Drug Profile

ALKS 4230

Alternative Names: ALKS-4230; RDB 1450; RDB-1419

Latest Information Update: 03 Mar 2017

Price : $50

At a glance

  • Originator Alkermes plc
  • Class Antineoplastics; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 21 Feb 2017 Alkermes has patent protection for ALKS 4230 in USA (Alkermes plc 10-K, February 2017)
  • 25 May 2016 Phase-I clinical trials in Solid tumours (Second-line therapy or greater) in Ireland (IV)
  • 13 Apr 2015 Alkermes plans a phase I trial for RDB 1450 in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top